Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Rucaparib maintenance for recurrent ovarian carcinoma

Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses the use of rucaparib for the maintenance treatment of recurrent ovarian carcinoma, specifically highlighting data from the Phase III ARIEL3 trial (NCT01968213). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.